Cached score snapshot
US.RMD · ResMed
110分制 63.8/110;5D動能v2 5/50;排序分 68.8/160 · Incomplete inputs
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling DOE best | -0.26% | -2.61% / +1.87% | 43.8% | 7.5% | Actual -2.49% · vs median -2.23% · inside 25-75 band |
| 30D observation | +7.81% | +0.98% / +14.98% | 82.5% | 3.8% | Actual outcome pending · 1 / 30 bars observed |
| Historical projection 10D n=160 | -0.26% | -2.10% / +2.17% | 45% | 7.5% | Actual outcome pending · 1 / 10 bars observed |
歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。
2026-05-18 → 2026-09-23 · 201 archived points · 3 Improving turn signal · 8 Deteriorating signal · 2 Exit review signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 19.6 · 資金流 18 · 5D動能v2 5 · Incomplete inputs
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Incomplete score
此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。
- VIX_MISSING: VIX market context is required for market environment scoring
Market inputs
Metrics snapshot
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
基本面 — 4.3/5 · 優秀
Sub-items
資金流 — 18/20 · 優秀
Sub-items
institutional
details
warning
市場環境 — 6.2/15 · 較差
Sub-items
vix
details
trend
details
qqq
spy
催化劑 — 6/20 · 較差
Sub-items
catalyst
details
風險管理 — 5.7/10 · 較差
Sub-items
position
details
stopLevels
strength_details
diversification
details
技術信號 — 19.6/30 · 一般
Sub-items
vcpPayload
vcp_metrics
情緒分析 — 4/10 · 較差
Sub-items
sentiment
details
sentimentData
Dimension contribution
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
Risk management
position
details
stopLevels
strength_details
diversification
details
Calculation audit log
基本面分析總分: 4.3/5分 資金流分析總分: 18/20分 市場環境分析總分: 6.2/15分 催化劑分析: 6/20分 風險管理總分: 5.7/10分 技術信號分析總分: 19.6/30分 情緒分析: 4/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
atr
cci
cmf
kdj
mfi
obv
rsi
sar
ma50
macd
vwap
volume
derived
ma_cross
bollinger
rsi_short
macd_short
volume_ratio
Raw calculation JSON
{
"risk": {
"level": "Elevated",
"reason": "risk management score >= 5/10",
"position": {
"score": 1.1,
"details": {
"atrPct": 3.761681415929204,
"turnoverUsdM": 237.196266,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RMD",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 208.9972,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 0.5,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 7.5,
"take_profit_price": 239.6022,
"target_multiplier": 1.6,
"technical_strength": 1.5,
"take_profit_percent": 6
},
"positionPoints": 1.1,
"stopLossPoints": 1.2,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 7.523362831858408,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 68.8,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 63.8,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 5
},
"market": {
"ma20": 209.5265,
"ma50": 202.1624,
"close": 226,
"prevClose": 224.84,
"avgVolume20": 1390437,
"volumeRatio": 0.75,
"changePercent": 0.52
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 5,
"details": {
"ret_5d": 0.008793469663855191,
"max_score": 50,
"max_total": 50,
"raw_total": 5,
"vcp_bonus": 0,
"vol_ratio": 0.7505298913043478,
"ret_points": 4,
"vol_points": 0,
"range_ratio": 1.130661965245132,
"volat_points": 0,
"day_range_pct": 0.03486725663716825,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 0,
"partial_history": false,
"pullback_points": 1,
"breakout_vol_bonus": 0,
"first_breakout_20d": false,
"return_window_days": 5,
"first_breakout_bonus": 0,
"breakout_quality_points": 0
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 68.8,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 4.3,
"label": "基本面",
"weight": "5/110",
"normalized": 86,
"contribution": 4.3
},
{
"raw": 18,
"label": "資金流",
"weight": "20/110",
"normalized": 90,
"contribution": 18
},
{
"raw": 6.2,
"label": "市場環境",
"weight": "15/110",
"normalized": 41.33,
"contribution": 6.2
},
{
"raw": 6,
"label": "催化劑",
"weight": "20/110",
"normalized": 30,
"contribution": 6
},
{
"raw": 5.7,
"label": "風險管理",
"weight": "10/110",
"normalized": 57,
"contribution": 5.7
},
{
"raw": 19.6,
"label": "技術信號",
"weight": "30/110",
"normalized": 65.33,
"contribution": 19.6
},
{
"raw": 4,
"label": "情緒分析",
"weight": "10/110",
"normalized": 40,
"contribution": 4
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "incomplete",
"standard110": {
"rating": "觀望",
"result": 63.8,
"details": [
"基本面分析總分: 4.3/5分",
"資金流分析總分: 18/20分",
"市場環境分析總分: 6.2/15分",
"催化劑分析: 6/20分",
"風險管理總分: 5.7/10分",
"技術信號分析總分: 19.6/30分",
"情緒分析: 4/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 6,
"基本面": 4.3,
"資金流": 18,
"市場環境": 6.2,
"情緒分析": 4,
"技術信號": 19.6,
"風險管理": 5.7
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 6,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 8,
"catalystCount": 1
}
},
"catalystPoints": 6
}
},
"基本面": {
"max": 5,
"grade": "優秀",
"items": {
"pbPoints": 0.2,
"pePoints": 0.4,
"epsPoints": 0,
"roePoints": 0.75,
"debtPoints": 0.5,
"marginPoints": 0.75,
"turnoverUsdM": 237.196266,
"volumePoints": 0.5,
"revenuePoints": 0.4,
"dividendPoints": 0.3,
"marketCapPoints": 0.5
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "優秀",
"items": {
"cmfPoints": 4,
"mfiPoints": 4,
"obvPoints": 4,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.RMD",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "較差",
"items": {
"vix": {
"score": 0,
"details": {
"source": "twelvedata+fred",
"missing": true,
"vixClose": null
}
},
"trend": {
"score": 3.4,
"details": {
"qqq": {
"ma20": 701.0319982000001,
"ma50": 713.49480132,
"name": "QQQ",
"close": 723.70001,
"points": 1.4
},
"spy": {
"ma20": 753.1860015999998,
"ma50": 748.1182043399999,
"name": "SPY",
"close": 772.48999,
"points": 2
},
"source": "twelvedata+fred"
}
},
"atrPct": 3.761681415929204,
"atrPoints": 2,
"cciPoints": 0.8,
"vixPoints": 0,
"marketTrendPoints": 3.4
}
},
"情緒分析": {
"max": 10,
"grade": "較差",
"items": {
"sentiment": {
"score": 4,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 8,
"negativeHits": 0,
"positiveHits": 3,
"sentimentScoreRaw": 0.9
}
},
"sentimentData": {
"raw": [
{
"id": 141172251,
"url": "https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
"category": "company",
"datetime": 1786340002,
"headline": "RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"
},
{
"id": 141149640,
"url": "https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.",
"category": "company",
"datetime": 1786115520,
"headline": "RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"
},
{
"id": 141144733,
"url": "https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.",
"category": "company",
"datetime": 1786079567,
"headline": "ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."
},
{
"id": 141143188,
"url": "https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e",
"image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"source": "SeekingAlpha",
"related": "RMD",
"summary": "ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...",
"category": "company",
"datetime": 1786053258,
"headline": "ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"
},
{
"id": 141142416,
"url": "https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
"category": "company",
"datetime": 1786052824,
"headline": "ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"
},
{
"id": 141142417,
"url": "https://finnhub.io/api/news?id=f9835639451fee0e6b3630315db2f0c70a6a253a6d8916bc5d7a11ff366e728e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
"category": "company",
"datetime": 1786052409,
"headline": "ResMed (RMD) Q4 Earnings and Revenues Top Estimates"
},
{
"id": 141139799,
"url": "https://finnhub.io/api/news?id=3c4e732c0a08f2d876c2a482f4d79b93814f8d2b83bdda5964d532f85e4bc1a0",
"image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "ResMed (RMD) Q4 revenue slightly misses, EPS beats; stock dips ~2% on profit-taking despite record results and raised dividend.",
"category": "company",
"datetime": 1786050938,
"headline": "ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9%"
},
{
"id": 141134279,
"url": "https://finnhub.io/api/news?id=24ccbb918500a4321fa00cad22c2de330360be3abbadfb067d8963d2611deb98",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46b for the period. See our latest analysis for ResMed. ResMed shares have climbed in recent weeks, with a 7 day share price return of 4.55% and a 90 day share price return of 8.28%. However, the year to date share price return is still down 8.49%, and the 1 year total shareholder return has...",
"category": "company",
"datetime": 1786022182,
"headline": "ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued"
}
],
"raw_source": [
{
"id": 141192693,
"url": "https://finnhub.io/api/news?id=1a51c3fda625137f05bd7a8622dd3db9cd4f97aa3ff563d6f1aa5511d9562da4",
"image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
"category": "company",
"datetime": 1786538101,
"headline": "Which S&P500 stocks are moving before the opening bell on Wednesday?"
},
{
"id": 141173748,
"url": "https://finnhub.io/api/news?id=36ece7701581afbc0c45cf4c64a289371a52775d64bb8b21d154e5aa1ad1a304",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.",
"category": "company",
"datetime": 1786360137,
"headline": "Resmed’s stock falls by 7% on soft FY27 outlook"
},
{
"id": 141172251,
"url": "https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
"category": "company",
"datetime": 1786340002,
"headline": "RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"
},
{
"id": 141164496,
"url": "https://finnhub.io/api/news?id=a45c6768cb0a925167bb2caabc3e4fdcc136f4362e935257ea82e41483442ced",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni",
"category": "company",
"datetime": 1786248229,
"headline": "ResMed Q4 Earnings Call Highlights"
},
{
"id": 141164828,
"url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "RMD",
"summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
"category": "company",
"datetime": 1786243803,
"headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
},
{
"id": 141150616,
"url": "https://finnhub.io/api/news?id=97cc30b60f13c7af214f0c0afb17997cc515ad12a36ad63fdf4d3ec954ca3f5c",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
"category": "company",
"datetime": 1786129501,
"headline": "Stay informed with the top movers within the S&P500 index on Friday."
},
{
"id": 141152423,
"url": "https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "RMD",
"summary": "Weekly dividend activity roundup for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates here.",
"category": "company",
"datetime": 1786125278,
"headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"
},
{
"id": 141149003,
"url": "https://finnhub.io/api/news?id=ef9e2796d2ec153c86f76a0efc5f8a7f4a4eab218d749fcd6a3713e33e419366",
"image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Friday's session.",
"category": "company",
"datetime": 1786122300,
"headline": "In today's session, there are S&P500 stocks with remarkable trading volume."
},
{
"id": 141148910,
"url": "https://finnhub.io/api/news?id=9bdba43fcab22b2cbe6b2e92788d4e69dd55e6b163385f9dbbc531c0004beafd",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.",
"category": "company",
"datetime": 1786120501,
"headline": "Top S&P500 movers in Friday's session"
},
{
"id": 141153610,
"url": "https://finnhub.io/api/news?id=162e6edef4356f7eb0c7235270c0972716ca4d6de76862bbf7006d9764dc6d8b",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.",
"category": "company",
"datetime": 1786119093,
"headline": "RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244"
},
{
"id": 141149640,
"url": "https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.",
"category": "company",
"datetime": 1786115520,
"headline": "RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"
},
{
"id": 141147567,
"url": "https://finnhub.io/api/news?id=ba7e0c36628e3e622f779f9a6b4fcefb13ededca266f41f5382d1d7a360c7967",
"image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
"category": "company",
"datetime": 1786113301,
"headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
},
{
"id": 141149831,
"url": "https://finnhub.io/api/news?id=ed83215398feaf5df6a377a600ecc89fd18ace8239fcbfea60c662d7e787cdcb",
"image": "https://cdn.benzinga.com/files/images/story/2026/08/07/SP-500.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RMD",
"summary": "U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.",
"category": "company",
"datetime": 1786109247,
"headline": "S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today"
},
{
"id": 141153612,
"url": "https://finnhub.io/api/news?id=e1469dc4cf1a9b93443bc8bde6236da05ac919be746cb5a96c540e9b8973bcff",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.",
"category": "company",
"datetime": 1786108086,
"headline": "Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225"
},
{
"id": 141147080,
"url": "https://finnhub.io/api/news?id=fb38d0e669c6ebb7a77e00e1f4b64b1991a2b958d779c41b6078dc5f53e51b92",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
"category": "company",
"datetime": 1786107416,
"headline": "Update: US Equity Futures Rise Pre-Bell as Traders Assess Jobs Report, Monitor Middle East Developments"
},
{
"id": 141147229,
"url": "https://finnhub.io/api/news?id=f5260272055fee7d9ab541f25d669d7f9cdde5e74466a245840c9fcc7e6a19f1",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (NYSE:RMD) shares declined 5. 5% in premarket trading after the medical device manufacturer reported fourth-quarter fiscal 2026 results that delivered an earnings beat but fell slightly short on revenue.",
"category": "company",
"datetime": 1786106465,
"headline": "ResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook"
},
{
"id": 141146666,
"url": "https://finnhub.io/api/news?id=073c54ac6a5c9a52cf67af390cc14433ee433ae80c98f88141a2bf1f9b5787c4",
"image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "Before the opening bell on Friday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
"category": "company",
"datetime": 1786106101,
"headline": "Which S&P500 stocks are moving before the opening bell on Friday?"
},
{
"id": 141153613,
"url": "https://finnhub.io/api/news?id=f42af4e01184cab1b7ec516f2215779f322997ffc7c5035bf6917b5b9f0241e5",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.",
"category": "company",
"datetime": 1786097629,
"headline": "Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255"
},
{
"id": 141153614,
"url": "https://finnhub.io/api/news?id=819e2b995fef2a78d1d9a608be1176eeb6975e3f90ffc8bd6d66e62a7b120924",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.",
"category": "company",
"datetime": 1786097490,
"headline": "Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215"
},
{
"id": 141147448,
"url": "https://finnhub.io/api/news?id=42771496d59a56028a962cf7d3e7928c840ba00554b95a93a821fabde9142024",
"image": "https://cdn.benzinga.com/files/images/story/2026/08/07/Portland--Or--Usa---Jan-21--2021-The-Tra.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RMD",
"summary": "US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.",
"category": "company",
"datetime": 1786089735,
"headline": "Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session"
},
{
"id": 141144733,
"url": "https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.",
"category": "company",
"datetime": 1786079567,
"headline": "ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."
},
{
"id": 141143188,
"url": "https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e",
"image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"source": "SeekingAlpha",
"related": "RMD",
"summary": "ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...",
"category": "company",
"datetime": 1786053258,
"headline": "ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"
},
{
"id": 141142416,
"url": "https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
"category": "company",
"datetime": 1786052824,
"headline": "ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"
},
{
"id": 141142417,
"url": "https://finnhub.io/api/news?id=f9835639451fee0e6b3630315db2f0c70a6a253a6d8916bc5d7a11ff366e728e",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
"category": "company",
"datetime": 1786052409,
"headline": "ResMed (RMD) Q4 Earnings and Revenues Top Estimates"
},
{
"id": 141142998,
"url": "https://finnhub.io/api/news?id=e266785fa8d8f2d00504ae73786d8ead1e0a5b1add3451405a963a5df2d9e061",
"image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"source": "SeekingAlpha",
"related": "RMD",
"summary": "2026-08-06. The following slide deck was published by ResMed Inc.",
"category": "company",
"datetime": 1786051868,
"headline": "ResMed Inc. 2026 Q4 - Results - Earnings Call Presentation"
},
{
"id": 141139799,
"url": "https://finnhub.io/api/news?id=3c4e732c0a08f2d876c2a482f4d79b93814f8d2b83bdda5964d532f85e4bc1a0",
"image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "ResMed (RMD) Q4 revenue slightly misses, EPS beats; stock dips ~2% on profit-taking despite record results and raised dividend.",
"category": "company",
"datetime": 1786050938,
"headline": "ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9%"
},
{
"id": 141140799,
"url": "https://finnhub.io/api/news?id=e661e2a1607bf2ad8fcb76dbef26ff8284d18411bf61d9c0b7cc5f4dc1110ed7",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70% Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX:",
"category": "company",
"datetime": 1786046700,
"headline": "Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026"
},
{
"id": 141141984,
"url": "https://finnhub.io/api/news?id=5ff0d18d32d01d3f09f4fc144fb8aa27a500d0047f05ed5443dde9968e6c51ad",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period",
"category": "company",
"datetime": 1786032357,
"headline": "ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate"
},
{
"id": 141134279,
"url": "https://finnhub.io/api/news?id=24ccbb918500a4321fa00cad22c2de330360be3abbadfb067d8963d2611deb98",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46b for the period. See our latest analysis for ResMed. ResMed shares have climbed in recent weeks, with a 7 day share price return of 4.55% and a 90 day share price return of 8.28%. However, the year to date share price return is still down 8.49%, and the 1 year total shareholder return has...",
"category": "company",
"datetime": 1786022182,
"headline": "ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued"
},
{
"id": 141125710,
"url": "https://finnhub.io/api/news?id=908443464c6dac93d7d144bad74f909237b4d1ce507acfbe554ffe8dd66c08d9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.",
"category": "company",
"datetime": 1785952740,
"headline": "Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?"
},
{
"id": 141125711,
"url": "https://finnhub.io/api/news?id=86654da613505d37a72deed55f1f4b51cbc7a004fc7b41b9e6fd5f1e19cb0c5a",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.",
"category": "company",
"datetime": 1785951300,
"headline": "INSP's 28.1% Past-Month Rally Raises a Key Question for Investors"
},
{
"id": 141122934,
"url": "https://finnhub.io/api/news?id=5ebdc3970abbb2a2338a21c3afa648199e0f3a8e8c03b36dd04d8ac65b339e0d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.",
"category": "company",
"datetime": 1785941820,
"headline": "What to Expect From These 2 MedTech Stocks This Earnings Season?"
},
{
"id": 141122755,
"url": "https://finnhub.io/api/news?id=679dc62b0d6341e0716993d69a4659ffa37cff052797d6fbc10f1828108e701d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
"category": "company",
"datetime": 1785935706,
"headline": "Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics"
},
{
"id": 141104327,
"url": "https://finnhub.io/api/news?id=352cc05ac2d4a26c5635f6fdf97bc1040f7f84f82a959edb3181f428a871c81d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Viemed Healthcare (VMD) delivered earnings and revenue surprises of -30.00% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
"category": "company",
"datetime": 1785797109,
"headline": "Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates"
},
{
"id": 141103236,
"url": "https://finnhub.io/api/news?id=124e694ad0b3e2f69b544333b87c4d5251ef48d8bf142f9f9ca9f8ba16d24cdb",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
"category": "company",
"datetime": 1785788962,
"headline": "1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky"
},
{
"id": 141079192,
"url": "https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.",
"category": "company",
"datetime": 1785504720,
"headline": "Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"
},
{
"id": 141078062,
"url": "https://finnhub.io/api/news?id=eccab60418f61c40d3a156f57c0957bf7084f81ce29971339390e78da2a7b84d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
"category": "company",
"datetime": 1785504709,
"headline": "3 Large-Cap Stocks to Consider Right Now"
},
{
"id": 141067141,
"url": "https://finnhub.io/api/news?id=2eba5c1a1a25c1b0f492d696ae339d2d6665a3f0234260cb85aab3bb8fd081ad",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
"category": "company",
"datetime": 1785420019,
"headline": "ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth"
},
{
"id": 141065678,
"url": "https://finnhub.io/api/news?id=627351a5866f253bd786f5ad7587b3fed6c6ee8ec3bbe68f04ebc325dd60a5ac",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
"category": "company",
"datetime": 1785414903,
"headline": "Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates"
},
{
"id": 140991410,
"url": "https://finnhub.io/api/news?id=a7d3773d8f60001c539390370a53abf66180cc30e499445d40c79aec749bde17",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.",
"category": "company",
"datetime": 1784791489,
"headline": "3 Cash-Heavy Stocks to Research Further"
},
{
"id": 140973578,
"url": "https://finnhub.io/api/news?id=d1da9496c35a7b3d8bb71682a817d89804339dc66aec5bf1446d9a2e13a70166",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales a",
"category": "company",
"datetime": 1784653509,
"headline": "ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says"
},
{
"id": 140919724,
"url": "https://finnhub.io/api/news?id=10d75e966d521449cb435e791208bb5a18a79c4ff41421920a9bd92a572ae747",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls",
"category": "company",
"datetime": 1784208834,
"headline": "SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls"
},
{
"id": 140915096,
"url": "https://finnhub.io/api/news?id=d54ea0e2611a9220a67326b3f5a2746c38f64336c0ec6ee0731941b9e851e380",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.",
"category": "company",
"datetime": 1784125957,
"headline": "Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220"
},
{
"id": 140907889,
"url": "https://finnhub.io/api/news?id=cbbc8a208dad1164a764fe1bf8c2fbc264cb3db72fa3d2cf377033fa4545b99a",
"image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
"source": "ChartMill",
"related": "RMD",
"summary": "Discover how the Best Dividend Stocks screen identifies sustainable payers like ResMed (RMD), combining high dividend ratings with strong profitability and health ratings for long-term stability.",
"category": "company",
"datetime": 1784119828,
"headline": "ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health"
},
{
"id": 140896086,
"url": "https://finnhub.io/api/news?id=314ee830610034b8e43e9f1ac6965abc1e3002ee4aa295e5d160599d325fc78b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RMD",
"summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
"category": "company",
"datetime": 1784024591,
"headline": "2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore"
},
{
"id": 140886292,
"url": "https://finnhub.io/api/news?id=0bb615d0359f2e54b7ebb837a70329209bcebadfe6eaa900635dfa26041c609e",
"image": "",
"source": "Fintel",
"related": "RMD",
"summary": "",
"category": "company",
"datetime": 1783950457,
"headline": "Citigroup Downgrades ResMed (RMD)"
},
{
"id": 140886507,
"url": "https://finnhub.io/api/news?id=a8b2c8f3e5e344f2a19f19bcb2204a6733a8d0ebc0ff3860ce7fd67951f1bc98",
"image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Beijing--China---June-4--2023-Keysight-S.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RMD",
"summary": "Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.",
"category": "company",
"datetime": 1783930266,
"headline": "Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday"
},
{
"id": 140891790,
"url": "https://finnhub.io/api/news?id=bc4c0c3007cde3881e550b7f3efaa125581edccfa93f7a00f5d3af4a166d5614",
"image": "",
"source": "Benzinga",
"related": "RMD",
"summary": "Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.",
"category": "company",
"datetime": 1783928623,
"headline": "Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 8,
"negative_hits": 0,
"positive_hits": 3,
"recomputed_at_score": true,
"sentiment_score_raw": 0.9,
"source_article_count": 48,
"discarded_article_count": 36
},
"sentimentPoints": 4
}
},
"技術信號": {
"max": 30,
"raw": 19.6,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 2.4000000000000004,
"vcpPoints": 0.9,
"macdPoints": 4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 0.9,
"vcp_reason": "站上MA50;升放量(近10日3日);Ready=N;Confirm=Y",
"vcp_metrics": {
"up_days": 6,
"vol_ref": 1517716.6666666667,
"down_days": 3,
"vcp_ready": false,
"above_ma50": true,
"avg_vol_10": 1703660,
"avg_vol_20": 1398400,
"avg_vol_30": 1517716.6666666667,
"range_pct_10": 0.10672566371681418,
"range_pct_20": 0.1588937610619469,
"range_pct_30": 0.1588937610619469,
"up_expand_ok": true,
"lookback_used": 59,
"near_20d_high": true,
"contraction_ok": false,
"down_shrink_ok": false,
"up_expand_days": 3,
"breakout_20d_ok": false,
"vol_ratio_10_30": 1.1225151817972172,
"dist_to_20d_high": 0.0005306916681408303,
"down_shrink_days": 1,
"breakout_level_20d": 226.12,
"vcp_breakout_confirm": true,
"contraction_ratio_10_30": 0.6716793850402076
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": false
},
"kdjAdxPoints": 0.7,
"rsiKdjPoints": 2.4,
"volumeWeight": 2,
"maCrossPoints": 1.6,
"shortRsiPoints": 0.8,
"shortMacdPoints": 0.4,
"volConfirmPoints": 0,
"volumePointsTechnical": 0.4
}
},
"風險管理": {
"max": 10,
"grade": "較差",
"items": {
"position": {
"score": 1.1,
"details": {
"atrPct": 3.761681415929204,
"turnoverUsdM": 237.196266,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RMD",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 208.9972,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 0.5,
"macd_score": 3,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 7.5,
"take_profit_price": 239.6022,
"target_multiplier": 1.6,
"technical_strength": 1.5,
"take_profit_percent": 6
},
"positionPoints": 1.1,
"stopLossPoints": 1.2,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 7.523362831858408,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [
{
"code": "VIX_MISSING",
"symbol": "US.RMD",
"message": "VIX market context is required for market environment scoring",
"missing": [
"VIX"
],
"provider": "scoring"
}
],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": false,
"missingFields": [
"VIX"
],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 100,
"atr": {
"atr": 8.5014,
"rule": "ATR / current price; lower volatility scores higher",
"score": 4,
"atr_pct": 3.76
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "超買或超賣風險",
"score": 2,
"value": 111.29
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "強累積",
"score": 10,
"value": 0.3841
},
"kdj": {
"d": 82.02,
"j": 95.87,
"k": 86.63,
"rule": "Cursor_18.24 K/D cross",
"score": 4,
"signal": "金叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "強資金流入",
"score": 10,
"value": 77.54
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 10,
"trend": "強流入",
"value": 3866441,
"recentSlope": 447684.1,
"previousSlope": -189840
},
"rsi": 74.45,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 8,
"trend": "上升",
"value": 207.0021,
"position": "SAR喺價下",
"distancePct": 8.41,
"previousTrend": "上升"
},
"ma50": 202.1624,
"macd": {
"macd": 6.210343455493216,
"trend": "強烈看漲",
"signal": 4.658504436225714,
"histogram": 1.5518390192675025
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 210.0195,
"position": "連續5日>VWAP",
"consecutiveAbove": 13
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "空升",
"ratio": 0.75,
"score": 2,
"avgVolume": 1390437,
"currentVolume": 1049541
},
"derived": {
"ma20": 209.5265,
"ma50": 202.1624,
"prevClose": 224.84,
"avgVolume10": 1676084,
"avgVolume20": 1390437,
"changePercent": 0.52,
"avgVolumeForScore": 1390437
},
"ma_cross": {
"ma20": 209.5265,
"ma50": 202.1624,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "多頭",
"score": 4,
"prevMa20": 208.155,
"prevMa50": 201.3712,
"spreadPct": 3.64,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 186.8961,
"upper": 232.1569,
"position": "上半部"
},
"rsi_short": 55.29,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 0.75
}
}
}
Raw metrics JSON
{
"close": 226,
"volume": 1049541,
"changePercent": 0.52
}
Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.